Shots:

• AKSO will be eligible to receive ~$75M including up front, R&D funding, a regulatory and commercial milestone & is also eligible to receive royalties from future product sales. AKSO will obtain all rights to AB002 globally
• Huadong Medicine will lead the clinical development, regulatory submissions, and commercialization of AB002 in the region and jointly conduct IND-enabling tasks with AKSO via the Joint Research Committee. AKSO will continue to be responsible for the development of AB002 globally
• The collaboration will use Huadong Medicine’s leading expertise and experience in drug development to advance the development of AB002  to benefit cancer patients globally

Ref: Businesswire | Image: Businesswire